8:45AM to 9:10AM
Market recap - Scope of industry size and market; George Paraskevakos, IPA

9:15AM to 9:45AM
Dr David Keller, Ganeden
Probiotics Labelling and Best Practices Guideline
The reality of our sector and how probiotics are unique and have different requirements for areas such as quantification, stability

9:50AM to 11:40PM
Analytical methodologies and potential new technologies:
Dr. Marco Pane, Probiotical and Dana Buckman, Bioform Solutions
Flow Cytometry - Evolution of microbiological analytical method for industry and research needs.

Dr Chris Elkins, FDA
Genomic analysis of beneficial microbes - supporting industry and regulation with innovative science.

Buffy Stahl, Dupont
The use of the phosphoglucose isomerase gene for detection of multiple species in blends of probiotic dietary supplements
11:45AM to 12:10PM
Stephen Daniells, WRBM and George Paraskevakos, IPA
Case analysis: Press vs Reality – analyzing the gaps.

12:15PM to 1:10PM
Lunch

1:15PM to 2:30PM
New dietary ingredients notification (2016 draft)
Dr. Greg Leyer, UAS Labs
Scientific approach to probiotic safety and the NDI chemical alteration standard

Solange Henoud, Lallemand Health Solutions
IPA draft position on the revised NDI guidance

Dr Cara Welch FDA
NDI draft comments

2:35PM to 3:05PM
Richard Cleland FTC
The Regulation of Probiotic Claims in Advertising:
Don’t Let it Bug You
FTC’s position in regards to activities and marketing probiotic supplements
3:10PM to 3:40PM
Richard Bonnette, FDA
The GRAS Final Rule: Overview and Implications for FDA’s GRAS Notification Process

3:45PM to 4:30PM
Closing Panel
IPA Counsel Insights on FDA and FTC issues, including NDIs and Claim Substantiation.
Speakers to include Dr. Cara Welch, Richard L. Cleland, Ashish Talati, Esq. and Ivan Wasserman, Esq. of Amin Talati Upadhye, LLP

4:30 PM
Close out and thank you.